Compare Stocks → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALRNNASDAQ:COCPNASDAQ:ONTXNASDAQ:OTICNASDAQ:TPST Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRNAileron Therapeutics$4.16-8.6%$5.43$1.01▼$7.42$70.60M2.2274,160 shs483,852 shsCOCPCocrystal Pharma$1.53-1.3%$1.49$1.33▼$3.29$15.57M1.3413,227 shs23,045 shsONTXOnconova Therapeutics$0.85$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ATPSTTempest Therapeutics$3.62+4.3%$3.70$0.17▼$9.77$80.44M-1.76915,897 shs258,314 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRNAileron Therapeutics-7.52%-4.21%-31.37%+2.94%+213.79%COCPCocrystal Pharma+2.34%+1.15%+12.86%-0.63%-34.71%ONTXOnconova Therapeutics0.00%0.00%-1.46%+46.15%-11.92%OTICOtonomy0.00%0.00%0.00%0.00%0.00%TPSTTempest Therapeutics+0.87%+1.46%-11.25%-8.44%+57.73%Have You Seen Elon’s New A.I. Device? (Picture Inside) (Ad)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat...MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRNAileron Therapeutics1.9592 of 5 stars3.53.00.00.02.41.70.0COCPCocrystal Pharma3.4675 of 5 stars3.55.00.00.02.81.71.3ONTXOnconova Therapeutics0.7872 of 5 stars3.53.00.00.00.00.00.0OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/ATPSTTempest Therapeutics0.8196 of 5 stars3.52.00.00.01.10.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRNAileron Therapeutics3.00Buy$19.00356.73% UpsideCOCPCocrystal Pharma3.00Buy$10.00553.59% UpsideONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideOTICOtonomyN/AN/AN/AN/ATPSTTempest Therapeutics3.00Buy$25.00590.61% UpsideCurrent Analyst RatingsLatest ALRN, TPST, OTIC, ONTX, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024ALRNAileron TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $19.004/4/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/20/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/20/2024TPSTTempest TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/20/2024TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.003/14/2024TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$13.002/8/2024TPSTTempest TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRNAileron TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACOCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00OTICOtonomy$130K4.48N/AN/A$0.97 per share0.01TPSTTempest TherapeuticsN/AN/AN/AN/A$1.39 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRNAileron Therapeutics-$15.73M-$3.38N/AN/AN/AN/A-130.32%-39.23%5/13/2024 (Estimated)COCPCocrystal Pharma-$17.98M-$1.99N/AN/AN/AN/A-59.62%-54.62%5/20/2024 (Estimated)ONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ATPSTTempest Therapeutics-$29.49M-$1.91N/AN/AN/AN/A-283.87%-82.11%5/8/2024 (Estimated)Latest ALRN, TPST, OTIC, ONTX, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q4 2023ALRNAileron TherapeuticsN/A-$1.54-$1.54-$1.54N/AN/A3/28/2024Q4 2023COCPCocrystal Pharma-$0.57-$0.44+$0.13-$0.44N/AN/A3/19/2024Q4 2023TPSTTempest Therapeutics-$0.38-$0.34+$0.04-$0.34N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRNAileron TherapeuticsN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRNAileron TherapeuticsN/A4.174.17COCPCocrystal PharmaN/A8.928.92ONTXOnconova TherapeuticsN/A2.792.79OTICOtonomyN/A1.741.74TPSTTempest Therapeutics0.234.294.29OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRNAileron Therapeutics90.89%COCPCocrystal Pharma6.72%ONTXOnconova Therapeutics7.95%OTICOtonomy41.23%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipALRNAileron Therapeutics5.57%COCPCocrystal Pharma25.06%ONTXOnconova Therapeutics3.30%OTICOtonomy1.09%TPSTTempest Therapeutics5.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALRNAileron Therapeutics616.97 million16.03 millionNot OptionableCOCPCocrystal Pharma1210.17 million7.62 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableOTICOtonomy5168.53 million67.78 millionOptionableTPSTTempest Therapeutics1722.22 million20.93 millionOptionableALRN, TPST, OTIC, ONTX, and COCP HeadlinesSourceHeadlineTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 26 at 4:05 PMTempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Updatemarketbeat.com - April 13 at 1:10 PMTempest Therapeutics (NASDAQ:TPST) Trading Down 6.8%marketbeat.com - April 13 at 12:40 AMBuy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developmentsmarkets.businessinsider.com - April 9 at 5:53 PMTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meetingfinance.yahoo.com - April 9 at 12:51 PMTempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meetingglobenewswire.com - April 9 at 8:00 AMTempest Therapeutics moves TPST-1120 into phase 3 trialuk.investing.com - April 6 at 3:43 PMTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communicationsfinance.yahoo.com - April 4 at 8:14 AMTempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communicationsglobenewswire.com - April 4 at 8:00 AMPiper Sandler Keeps Their Buy Rating on Tempest Therapeutics (TPST)markets.businessinsider.com - March 21 at 6:39 AMTempest Therapeutics: Tempest Reports Year End 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 20 at 3:37 PMTPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023investorplace.com - March 19 at 11:07 PMTempest Reports Year End 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 19 at 8:50 PMTempest Reports Year End 2023 Financial Results and Provides Business Updateglobenewswire.com - March 19 at 4:25 PMGlancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)businesswire.com - March 14 at 3:56 PMBuy Rating Affirmed for Tempest Therapeutics Amid Strong TPST-1120 Preclinical and Financial Prospectsmarkets.businessinsider.com - March 12 at 8:31 PMTempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Typesfinance.yahoo.com - March 12 at 10:29 AMTempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meetingglobenewswire.com - March 5 at 4:30 PMTempest to Present at the 44th Annual TD Cowen Healthcare Conferencefinance.yahoo.com - February 26 at 2:06 PMTempest Therapeutics, Inc. (TPST)finance.yahoo.com - January 30 at 12:57 PMTempest Therapeutics Stock (NASDAQ:TPST), Short Interest Reportbenzinga.com - December 28 at 12:21 AMTempest Therapeutics Stock (NASDAQ:TPST) Insider Tradesbenzinga.com - December 11 at 8:37 AMTempest Therapeutics: Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - December 2 at 1:56 PMTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - December 1 at 6:42 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackCanoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetApril 2, 2024 9:15 AMView Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AIIntuitive Surgical Leads the Robotic Surgery MovementApril 22, 2024 6:10 AMView Intuitive Surgical Leads the Robotic Surgery MovementCan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsAileron TherapeuticsNASDAQ:ALRNAileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Cocrystal PharmaNASDAQ:COCPCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.OtonomyNASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Tempest TherapeuticsNASDAQ:TPSTTempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.